This Insight Brief delves into the rapidly evolving landscape of clinical research for cell and gene therapies (CAGT) in autoimmune diseases. As the industry’s focus expands beyond oncology, the autoimmune space is emerging as a frontier of both opportunity and complexity. This brief examines the critical need for integrated strategic planning across clinical development, regulatory navigation and patient engagement to successfully advance CAGT in this challenging therapeutic area.

Authored by leading experts from IQVIA Biotech and IQVIA, the brief emphasizes the importance of early, data-driven decision-making to accelerate innovation and improve outcomes in autoimmune disease treatment. It serves as a valuable resource for stakeholders aiming to navigate the unique scientific, operational and regulatory demands of this dynamic field.

Want more? Watch the webinar presentation on-demand